4.5 Article

Characterization of Two Mutations in the SPTLC1 Subunit of Serine Palmitoyltransferase Associated with Hereditary Sensory and Autonomic Neuropathy Type I

期刊

HUMAN MUTATION
卷 32, 期 6, 页码 E2211-E2225

出版社

WILEY-BLACKWELL
DOI: 10.1002/humu.21481

关键词

HSAN-I; SPTLC1; serine palmitoyltransferase; 1-deoxy-sphinganine

资金

  1. University of Antwerp
  2. Fund for Scientific Research (FWO-Flanders)
  3. Medical Foundation Queen Elisabeth (GSKE)
  4. 'Association Belge contre les Maladies Neuromusculaires' (ABMM)
  5. Belgian Federal Science Policy Office (BELSPO) [P6/43]
  6. Institute for Science and Technology (IWT)
  7. EMBO
  8. BELSPO
  9. German Society for Clinical Chemistry and Laboratory Medicine (DGKL)
  10. Gebert Ruf Foundation
  11. European Commission [LSHM-CT-2006-037631]

向作者/读者索取更多资源

Hereditary sensory and autonomic neuropathy type I (HSAN-I) is an axonal peripheral neuropathy leading to progressive distal sensory loss and severe ulcerations. Mutations in SPTLC1 and SPTLC2, encoding the two subunits of serine palmitoyltransferase (SPT), the enzyme catalyzing the first and rate-limiting step in the de novo synthesis of sphingolipids, have been reported to cause HSAN-I. Here, we demonstrate that the SPTLC1 mutations p.S331F and p. A352V result in a reduction of SPT activity in vitro and are associated with increased levels of the deoxysphingoid bases 1-deoxy-sphinganine and 1-deoxymethyl-sphinganine in patients' plasma samples. Stably expressing p.S331F-SPTLC1 HEK293T cell lines likewise show accumulation of deoxysphingoid bases, but this accumulation is not observed in HEK293T cells overexpressing p.A352V-SPTLC1. These results confirm that the increased formation of deoxysphingoid bases is a key feature for HSAN-I as it is associated with all pathogenic SPTLC1 and SPTLC2 mutations reported so far, but also warrant for caution in the interpretation of in vitro data. (C) 2011 Wiley-Liss, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据